Agomab’s Crohn’s Drug Shows Promising Phase 2a Results
In the 12-week randomized Part A of the Phase 2a STENOVA study (n=103), ontunisertib met its primary endpoint with...
Obagi Shares New Clinical Data on Injectables & Scalp Serum
A randomized, multicenter pivotal trial in midface augmentation and associated nasolabial fold improvement showed Obagi’s saypha ChIQ achieved non-inferiority...
Trinity Biotech to Advance Prostate Cancer Test with Partner
An earlier study reported that when combined with PSA, Trinity Biotech’s EpiCapture correctly identified all high-grade prostate cancers in...
MIMEDX Provides Update on EpiEffect® Randomized Trial
Interim results from the CAMPAIGN randomized controlled trial reported a 98.5% posterior probability that lyophilized human amnion/chorion membrane (EPIEFFECT)...
New Data Confirms Test Performance for Low-Risk Patients
In a prospective multicenter analysis, Castle Biosciences’ i31-SLNB algorithm had an AUC of 0.74, compared with 0.61 for the...
Biox-101 Data Shows Breakthrough Potential for Stroke Care
Bioxodes reported encouraging Phase 2a signals for BIOX-101 in intracerebral hemorrhage, including a reduction in hematoma among all treated...
Obagi Presents New Clinical Data on Injectables at ASDS 2025
A randomized, multicenter pivotal trial found Obagi saypha ChIQ noninferior to Juvéderm Voluma XC for midface volume restoration, with...
Tenaya’s TN-201 Gene Therapy Shows Promise for MYBPC3 HCM
In interim data from the MyPEAK-1 Phase 1b/2a study of TN-201 in MYBPC3-associated hypertrophic cardiomyopathy, three patients treated at...
MHRA Approves Trial for Unresectable Pancreatic Cancer
The UK’s MHRA has cleared a clinical investigation of YntraDose, a percutaneous, intratumoral Yttrium-90 (Y-90) radiotherapy device for unresectable...
Breakthrough Needle Tech Succeeds in First Human Dialysis Study
No quantitative performance metrics were disclosed, but X9 reported successful first-in-human feasibility of its handheld ultrasound-guided, power-assisted needle insertion...